Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953662904> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2953662904 abstract "Exosomes are natural and abundant nanoscale vesicles for intercellular communication, capable of transferring biological instructions between neighboring and distant cell types. Translational research efforts have focused on exploiting this communication mechanism to deliver exogenous pharmacologic payloads to treat a variety of diseases including cancer. Functionalization of the exosome surface with proteins and peptides is an important strategy to maximize the potential of exosomes as therapeutics. Comparative proteomic analysis (LC/MS) of stringently purified exosomes led to the identification of several highly enriched and unique proteins, including a transmembrane glycoprotein (Protein X, PrX), belonging to the immunoglobulin superfamily. Stable expression of PrX in a producer cell line resulted in a 200-fold increase of PrX on the secreted exosomes. Protein X was extensively characterized and the minimum structural requirements for exosome enrichment were determined. With our engEx TM platform, we developed precision engineered exosome therapeutics using PrX as a scaffold to enable high-density exosome surface display of an array of structurally and biologically diverse proteins, including enzymes, antibodies, type I cytokines, and TNF superfamily members. These proteins were genetically fused to PrX and overexpressed in a producer cell. Significantly higher transgene expression on secreted exosomes was achieved compared to conventional scaffolds, including the tetraspanins CD9/CD63/CD81 and LAMP2B. Oligomerization of PrX coupled with avidity effects inherent in exosome surface display resulted in a clear activity advantage compared to free protein. Protein X-mediated display of CD40L on exosomes resulted in a 20-fold potency increase in B cell activation over recombinant CD40L. Furthermore, expression of CD40L redirected exosome uptake from phagocytic antigen presenting cells (APCs) to B cells, demonstrating exosome surface modifications can alter cellular tropism. We also evaluated the functionality of IL-12 tethered to the exosome surface and demonstrated superior tumor retention compared to free cytokine, resulting in robust anti-tumor activity in anti-PD-1 refractory B16F10 tumor models. These results demonstrate the potential of the engEx TM platform to generate novel exosome therapeutics. Citation Format: Kevin Dooley, Ke Xu, Sonya Haupt, Nuruddeen Lewis, Rane Harrison, Shelly Martin, Christine McCoy, Chang Ling Sia, Su Chul Jang, Katherine Kirwin, Russell McConnell, Bryan Choi, Adam T. Boutin, Damian Houde, Jorge Sanchez-Salazar, Agata Villiger-Oberbek, Kyriakos D. Economides, John D. Kulman, Sriram Sathyanarayanan. engEx: A novel exosome engineering platform enabling targeted transfer of pharmacological molecules [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2150." @default.
- W2953662904 created "2019-07-12" @default.
- W2953662904 creator A5009974780 @default.
- W2953662904 creator A5013049502 @default.
- W2953662904 creator A5013513429 @default.
- W2953662904 creator A5020844357 @default.
- W2953662904 creator A5021709595 @default.
- W2953662904 creator A5022418330 @default.
- W2953662904 creator A5023339605 @default.
- W2953662904 creator A5040574740 @default.
- W2953662904 creator A5042391451 @default.
- W2953662904 creator A5044756645 @default.
- W2953662904 creator A5046407682 @default.
- W2953662904 creator A5051594323 @default.
- W2953662904 creator A5059284128 @default.
- W2953662904 creator A5061907581 @default.
- W2953662904 creator A5063920766 @default.
- W2953662904 creator A5076126056 @default.
- W2953662904 creator A5080691423 @default.
- W2953662904 creator A5087187254 @default.
- W2953662904 creator A5090691725 @default.
- W2953662904 date "2019-07-01" @default.
- W2953662904 modified "2023-09-25" @default.
- W2953662904 title "Abstract 2150: engEx: A novel exosome engineering platform enabling targeted transfer of pharmacological molecules" @default.
- W2953662904 doi "https://doi.org/10.1158/1538-7445.sabcs18-2150" @default.
- W2953662904 hasPublicationYear "2019" @default.
- W2953662904 type Work @default.
- W2953662904 sameAs 2953662904 @default.
- W2953662904 citedByCount "0" @default.
- W2953662904 crossrefType "proceedings-article" @default.
- W2953662904 hasAuthorship W2953662904A5009974780 @default.
- W2953662904 hasAuthorship W2953662904A5013049502 @default.
- W2953662904 hasAuthorship W2953662904A5013513429 @default.
- W2953662904 hasAuthorship W2953662904A5020844357 @default.
- W2953662904 hasAuthorship W2953662904A5021709595 @default.
- W2953662904 hasAuthorship W2953662904A5022418330 @default.
- W2953662904 hasAuthorship W2953662904A5023339605 @default.
- W2953662904 hasAuthorship W2953662904A5040574740 @default.
- W2953662904 hasAuthorship W2953662904A5042391451 @default.
- W2953662904 hasAuthorship W2953662904A5044756645 @default.
- W2953662904 hasAuthorship W2953662904A5046407682 @default.
- W2953662904 hasAuthorship W2953662904A5051594323 @default.
- W2953662904 hasAuthorship W2953662904A5059284128 @default.
- W2953662904 hasAuthorship W2953662904A5061907581 @default.
- W2953662904 hasAuthorship W2953662904A5063920766 @default.
- W2953662904 hasAuthorship W2953662904A5076126056 @default.
- W2953662904 hasAuthorship W2953662904A5080691423 @default.
- W2953662904 hasAuthorship W2953662904A5087187254 @default.
- W2953662904 hasAuthorship W2953662904A5090691725 @default.
- W2953662904 hasConcept C104317684 @default.
- W2953662904 hasConcept C145059251 @default.
- W2953662904 hasConcept C185592680 @default.
- W2953662904 hasConcept C20518536 @default.
- W2953662904 hasConcept C2781261824 @default.
- W2953662904 hasConcept C55493867 @default.
- W2953662904 hasConcept C86803240 @default.
- W2953662904 hasConcept C95444343 @default.
- W2953662904 hasConceptScore W2953662904C104317684 @default.
- W2953662904 hasConceptScore W2953662904C145059251 @default.
- W2953662904 hasConceptScore W2953662904C185592680 @default.
- W2953662904 hasConceptScore W2953662904C20518536 @default.
- W2953662904 hasConceptScore W2953662904C2781261824 @default.
- W2953662904 hasConceptScore W2953662904C55493867 @default.
- W2953662904 hasConceptScore W2953662904C86803240 @default.
- W2953662904 hasConceptScore W2953662904C95444343 @default.
- W2953662904 hasLocation W29536629041 @default.
- W2953662904 hasOpenAccess W2953662904 @default.
- W2953662904 hasPrimaryLocation W29536629041 @default.
- W2953662904 hasRelatedWork W1219176874 @default.
- W2953662904 hasRelatedWork W1978699950 @default.
- W2953662904 hasRelatedWork W2020032658 @default.
- W2953662904 hasRelatedWork W2038236600 @default.
- W2953662904 hasRelatedWork W2047521139 @default.
- W2953662904 hasRelatedWork W2067688271 @default.
- W2953662904 hasRelatedWork W2071520532 @default.
- W2953662904 hasRelatedWork W2142823242 @default.
- W2953662904 hasRelatedWork W2278567201 @default.
- W2953662904 hasRelatedWork W2327541311 @default.
- W2953662904 hasRelatedWork W2339285831 @default.
- W2953662904 hasRelatedWork W2476046916 @default.
- W2953662904 hasRelatedWork W2771127919 @default.
- W2953662904 hasRelatedWork W2887707745 @default.
- W2953662904 hasRelatedWork W2955987967 @default.
- W2953662904 hasRelatedWork W3028170824 @default.
- W2953662904 hasRelatedWork W3084192008 @default.
- W2953662904 hasRelatedWork W3098107177 @default.
- W2953662904 hasRelatedWork W3199710062 @default.
- W2953662904 hasRelatedWork W3156219553 @default.
- W2953662904 isParatext "false" @default.
- W2953662904 isRetracted "false" @default.
- W2953662904 magId "2953662904" @default.
- W2953662904 workType "article" @default.